XML 33 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue:      
Total revenue $ 176,319 $ 256,577 $ 212,958
Operating costs and expenses:      
Cost of goods sold $ 8,869 $ 1,147 $ 0
Cost, Product and Service [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Research and development $ 252,924 $ 209,265 $ 235,839
Selling, general and administrative 106,406 135,479 63,812
Total operating costs and expenses 368,199 345,891 299,651
Loss from operations (191,880) (89,314) (86,693)
Interest and other, net      
Interest expense (2,402) (2,876) (10,991)
Investment loss in unconsolidated variable interest entity (202) 0 0
Interest income and other, net 5,553 15,548 11,568
Total interest and other, net 2,949 12,672 577
Loss before income taxes (188,931) (76,642) (86,116)
Provision for income taxes 360 328 304
Net loss $ (189,291) $ (76,970) $ (86,420)
Net loss per share - basic and diluted $ (2.11) $ (0.89) $ (1.03)
Weighted average number of common shares used to calculate net loss per share - basic and diluted 89,854 86,633 84,062
License Revenue [Member]      
Revenue:      
Total revenue $ 14,323 $ 177,086 $ 22,269
Development and Other Revenue [Member]      
Revenue:      
Total revenue 80,592 114,115 125,913
Product Revenue, Net [Member]      
Revenue:      
Total revenue 72,498 1,700 0
Drug Product Revenue [Member]      
Revenue:      
Total revenue $ 8,906 $ (36,324) $ 64,776